Background: Integrin receptors, composed of transmembrane a and b subunits, are essential for the development and functioning of multicellular animals. Agonist stimulation leads cells to regulate integrin affinity (''activation''), thus controlling cell adhesion and migration, controlling extracellular-matrix assembly, and contributing to angiogenesis, tumor cell metastasis, inflammation, the immune response, and hemostasis. A final step in integrin activation is the binding of talin, a cytoskeletal protein, to integrin b cytoplasmic domains. Many different signaling molecules that regulate integrin affinity have been described, but a pathway that connects agonist stimulation to talin binding and activation has not been mapped. Results: We used forward, reverse, and synthetic genetics to engineer and order an integrin activation pathway in cells expressing a prototype activatable integrin, platelet aIIbb3. Phorbol myristate acetate (PMA) activated aIIbb3 only after the increased expression of both recombinant protein kinase Ca (PKCa) and talin to levels approximating those in platelets. Inhibition of Rap1 GTPase reduced aIIbb3 activation, whereas activated Rap1A(G12V) bypassed the requirement for PKC, establishing that Rap1 is downstream of PKC. Talin binding to integrins mediates Rap1-induced activation because Rap1A(G12V) failed to activate aIIbb3 in cells expressing integrin binding-defective talin (W359A). Rap1 activated integrins by forming an integrin-associated complex containing talin in combination with the Rap effector, RIAM. Furthermore, siRNA-mediated knockdown of RIAM blocked integrin activation. Conclusions : We have, for the first time, ordered a pathway from agonist stimulation to integrin activation and established the Rap1-induced formation of an ''integrin activation complex,'' containing RIAM and talin, that binds to and activates the integrin.
Introduction
Agonist stimulation increases affinity (''activation'') of cellular integrins, a process central to physiological events such as cell migration, assembly of the extracellular matrix, the immune response, and hemostasis [1, 2] . Integrins are composed of type I transmembrane a and b subunits, each with a large extracellular domain, a single transmembrane domain, and a cytoplasmic domain (tail). The increase in ligand binding affinity is usually ascribable to changes in the conformation of the integrin extracellular domain [3] , the details of which remain a subject of lively debate. Mutational and molecular modeling studies suggest that rearrangements of the integrin a and b transmembrane domains result in the conformational change that occurs in the extracellular domain and is responsible for activation [4] [5] [6] [7] . Talin binds to most integrin b cytoplasmic domains via a structurally conserved PTB-like interaction, and the binding of the talin PTB-like domain to the integrin b tail initiates integrin activation [8] , presumably by causing the transmembrane-domain rearrangement. The broad biological significance of this process has resulted in a vast literature implicating different signaling pathways in integrin activation; however, there has not been a comprehensive dissection of the signaling elements that connect agonist receptors to the critical final step, talin binding.
The earliest studies of integrin activation concerned the platelet integrin aIIbb3 (GPIIb-IIIa). Many of the principles of function established with this integrin have proved widely applicable across the entire integrin family. In particular, the role of talin, the conserved membraneproximal domains, and specific structural motifs in the cytoplasmic domains in integrin activation are similar for most integrins [2] . Platelet agonists stimulate increased affinity of integrin aIIbb3 for soluble ligands coincident with talin redistribution to the plasma membrane [9] ; however, agonists fail to activate recombinant aIIbb3 expressed in chinese hamster ovary (CHO) cells or several other nucleated cells [10] . This puzzling observation has hindered the molecular dissection of the signaling pathways that regulate integrin activation. In the present study, we have used a synthetic approach to reconstruct an integrin activation pathway in CHO cells. We have then combined this approach with forward and reverse genetics to dissect a pathway to integrin activation. We show that Rap1-induced formation of an integrin activation complex containing the Rap1 effector, RIAM, and talin leads to the unmasking of the integrin binding site in talin-a final common step in integrin activation.
Results and Discussion
Reconstitution of Agonist-Induced Activation of Integrin aIIbb3 in a Nucleated Cell Platelet agonists stimulate increased affinity of integrin aIIbb3 for soluble ligands; however, agonists fail to activate recombinant aIIbb3 expressed in CHO cells or other nucleated cells [11] . Because talin binding is a final step in integrin activation and platelets express abundant talin relative to most nucleated cells [8] (Figure 1A ), we suspected that increasing talin would enable CHO cells to activate aIIbb3 in response to a platelet agonist, such as phorbol myristate acetate (PMA). Transfection of aIIbb3-expressing CHO cells (A5 cells) with cDNA encoding talin increased talin abundance to match that in platelets; however, this increased talin expression did not lead to PMA-stimulated binding of PAC-1, an activation-specific aIIbb3 antibody ( Figures 1A and 1B) . Protein kinase Ca (PKC) is highly expressed in platelets, is a major target of PMA, and has been implicated as a key downstream mediator in the activation of aIIbb3 by many platelet agonists [12] . A5 cells expressed PKCa at less than 12% of its abundance in platelets ( Figure 1A) ; cotransfection of PKCa with talin resulted in abundant expression of PKCa and PMA-stimulated PAC-1 binding. This effect also required high levels of talin expression because transfection with PKCa alone did not reconstitute aIIbb3 activation ( Figures 1B and 1C) . Moreover, reconstituted integrin activation required talin-integrin interaction because it did not occur when a talin mutant (W359A), which fails to bind to the b3 cytoplasmic tail [13] , was expressed instead of wildtype talin ( Figures 1B and 1C) . Furthermore, PMA induced talin redistribution to the plasma membrane in these doubly transfected cells ( Figure 1D ). Thus, increasing the abundance of talin and PKCa to levels found in platelets enabled CHO cells to manifest agonist-induced talin redistribution and activation of integrin aIIbb3.
Rap1 GTPase Is Downstream of PKC in Integrin aIIbb3 Activation
Talin is a known substrate for PKC [14, 15] . Recently, by use of a combination of immobilized metal-affinity chromatography and mass spectrometry, we mapped the phosphorylation sites in platelet talin 1 [16] (http:// www.cellmigration.org/resource/discovery/proteomics/ talin_total.shtml). To test the potential role of talin phosphorylation by PKC, we mutated all of the sites phosphorylated by PKCa in vitro (T144, T150, T430, and S446) [16] to alanines and examined the effect of these mutations on PKC-dependent integrin activation. None of these mutations affected PMA-stimulated aIIbb3 activation ( Figure S1A in the Supplemental Data available online). Thus, none of these talin phosphorylation sites are indispensable for integrin activation in this system.
Because talin phosphorylation by PKC did not appear to account for PKC-mediated integrin activation, we sought alternative explanations. Recent work from Shimizu's group found that PKC can activate and localize Rap1A GTPase by phosphorylating protein kinase D [17] . Rap1 is implicated in activation of b1, b2, and b3 integrins [18] [19] [20] [21] , leading us to examine its relationship to PKC in the integrin activation pathway. Rap1GAP (Rap GTPase-activating protein) expression, which specifically blocks Rap1-mediated signaling by converting active Rap1-GTP to inactive Rap1-GDP, almost completely inhibited PMA-induced aIIbb3 activation (Figure 2A) . Furthermore, expression of a dominant-active mutant of Rap1A [Rap1A (G12V)] could activate aIIbb3 in talin-transfected A5 cells in the absence of both PMA and transfected PKCa. A pharmacological inhibitor of PKC had no effect on Rap1-induced activation, indicating that PKC is not downstream of Rap1 in this pathway; however, this inhibitor efficiently blocked PMA-induced activation of aIIbb3 (Figure 2A ). Thus, Rap1 activity is downstream of PKC and is required for PMA-induced integrin activation.
Rap1-Mediated Integrin Activation Requires Talin
Previous work implicated both talin and Rap1 in integrin activation [8, 22] ; however, their relationship to each other has remained uncertain. Expression of dominant-active Rap1A(G12V) led to activation of aIIbb3 only in cells that had been cotransfected with talin (Figure 2B ). In contrast, Rap1A(G12V) failed to activate aIIbb3 in cells that had been transfected with the integrin binding-defective mutant, talin(W359A), indicating that talin binding to the integrin was required for Rap1-induced aIIbb3 activation. Rap1A(G12V) did not stimulate talin phosphorylation ( Figure S1B ), nor did it increase cleavage between the talin head and rod domains (Figure 2B ), two mechanisms hypothesized to induce talin binding and activation of integrins [23, 24] . Furthermore, mutations of multiple phosphorylation sites in talin or of the calpain cleavage site also failed to block Rap1-induced activation ( Figure 2C , Figure S1C ). Thus Rap1-mediated integrin activation requires talin binding to integrin b tails, suggesting that Rap1 is upstream of talin; however, activated Rap1 did not cause integrin activation by inducing talin cleavage or phosphorylation.
Rap1 induces integrin clustering in addition to conformational changes; either could lead to increased ligand binding affinity. We used the monovalent PAC-1 Fab fragment, which binds specifically to the active conformation of aIIbb3 and is insensitive to clustering [25] , to learn whether Rap1A was modulating integrin conformation. Coexpression of talin and Rap1 (G12V) enhanced PAC-1 Fab binding to aIIbb3 ( Figure S2 ). Thus, Rap1 induces talin-dependent integrin activation, at least in part, through a conformational change in the integrin.
The foregoing analysis showed that Rap1-mediated integrin activation requires talin when talin is overexpressed; however, it did not address the potential roles of endogenous Rap1 or talin in the context of integrin activation. When a chimera containing the cytoplasmic domain of a6A and b1A joined to the extracellular and transmembrane domains of aIIbb3 is expressed in CHO cells (abPy cells), it spontaneously binds PAC-1 in an energy-dependent manner [11] . PAC-1 binding to abPy cells was reduced by transfection of Rap1GAP, establishing that activation depended on Rap activity ( Figure S3A ). With chemical mutagenesis and selection, abPy variants have been identified that express the chimeric integrin, but lack the capacity to activate it [26] . One of these mutant cell lines (J1.1) was markedly deficient in talin expression ( Figure 3A ), and reconstitution of talin in this cell line rescued the activation defect ( Figure 3B ). Talin mutants (W359A and A360E), which exhibit reduced binding to the b3 [13] and b1A (Figure S3B) integrin tails, were ineffective in reconstituting PAC-1 binding, showing that reconstitution depended on talin binding to the integrin b tail ( Figure S3C ). abPy cells also express endogenous integrin a5b1 that binds to the cell binding domain of fibronectin [3FN (9-11)]. The J1.1 cells failed to bind 3FN (9-11) ( Figure 3C ), even though they expressed abundant a5b1. Binding was reconstituted by talin transfection (Figure 3C ), confirming that talin is also required for activation of endogenous b1 integrins in these cells. Transfection of J1.1 cells with Rap1A(G12V) failed to reconstitute activation, indicating that talin is indeed required for Rap1-mediated activation ( Figure 3D ). Moreover, two Rap1 effector proteins, RapL (NORE1B) [27] and RIAM [28] , alone or in combination with active Rap1A(G12V), failed to stimulate PAC-1 binding to talin-deficient cells, whereas talin alone rescued the activation defect ( Figure 3D ). Thus, talin is required for activation of b1 integrins, and these results now establish that the capacity of Rap1 and its effectors to activate b1 and b3 integrins is talin dependent.
Rap1 GTPase Activates Integrins by Regulating the Talin-Integrin Interaction
The requirement of talin for Rap1-mediated integrin activation suggests that talin is a downstream target of activated Rap1. The talin F3 domain contains the principal integrin binding site responsible for activation [13, 29] ; this site is completely available in the isolated talin head domain and its F23 fragment, but is masked in full-length talin [24] . In cells transfected with full-length talin, activated Rap1A(G12V) stimulated and Rap1GAP inhibited PAC-1 binding ( Figure 4A ). In sharp contrast, when these cells were transfected with talin F23, the increased PAC-1 binding was not blocked by cotransfection of Rap1GAP or enhanced by cotransfection of Rap1A (G12V) ( Figure 4A ). To further confirm that the talin F23 fragment could bypass the requirement for Rap1 activity, we tested abPy cells stably expressing a constitutively active integrin. In these cells, Rap1GAP reduced PAC-1 binding (w65%), and this reduction was reversed by coexpressed F23, but not by full-length talin (Figure S3A) . Thus, talin is required for Rap1-mediated activation, and an ''activated'' fragment of talin can bypass the need for Rap activity; talin is therefore downstream of Rap1 in this pathway.
Beckerle and coworkers found that stimuli that activate integrin aIIbb3 lead to the redistribution of talin from the platelet cytosol to the plasma membrane [9] , and we have now established that talin is a downstream target of Rap1 in integrin activation. Therefore, we asked whether activated Rap1 could induce a similar redistribution of talin to the plasma membrane. By subcellular fractionation, we found that expression of active Rap1A(G12V) increased the membrane localization of talin ( Figure 4B ), without changing the expression level of talin (data not shown). Immunoblotting for integrin aIIbb3 and RhoGDI established the authenticity of the isolated membrane and cytosolic fractions, respectively Twenty-four hours after transfection, cells were treated with either PMA (100 nM) or the PKC inhibitor, Bisindolylmaleimide (1 mM) and PAC-1 binding was assessed by flow cytometry (mean 6 SE; n R 3). Western blotting was used to verify protein expression. (B) Rap1-mediated integrin activation requires talin binding to integrin b cytoplasmic domain. A5 cells were transfected with talin (wild-type or W359A integrin binding-defective mutant) or with or without active Rap1A(G12V). After 24 hr, PAC-1 binding was measured by flow cytometry (mean 6 SE; n R 3). Protein expression was verified by western blotting. (C) Rap1-induced integrin activation is not mediated by calpain-dependent talin cleavage. PAC-1 binding to A5 cells transfected with either wildtype or calpain-resistant mutant GFP-talin (L432G) [36] in combination with Rap1A(G12V) and PAC-1 binding was assessed by flow cytometry, and protein expression was verified by western blotting.
( Figure 4B, right panel) . We confirmed this result by examining the localization of talin in cells transfected with GFP-talin. Cotransfection of talin with Rap1A(G12V) led to relocalization of talin to the plasma membrane within clusters that colocalized with aIIbb3 ( Figure 4C ). The Rap1-induced association of talin with integrin aIIbb3 was also observed in coimmunoprecipitation experiments. Cells were transfected with GFP-talin with or without active Rap1A(G12V) or Rap1GAP; a 3-fold increase in GFP-talin-associated aIIbb3 was seen in cells that had been cotransfected with Rap1A (G12V) but not with Rap1GAP ( Figure 4D , left panel) or with talin alone. Rap1GAP had reduced the slight activation observed in talin-transfected cells ( Figure 4A ), but did not reduce the small amount of talin coprecipitating with aIIbb3 in the absence of Rap1A(G12V) ( Figure 4D ). Thus, Rap1 stimulates the membrane localization and integrin association of talin.
RIAM Mediates the Formation of a Rap1-Induced Integrin Activation Complex
To see whether the Rap1 effectors RapL/NORE1B or RIAM couple Rap1 to talin, we expressed these proteins in talin-transfected cells. RIAM enhanced talin-mediated integrin activation, even in the absence of Rap1A(G12V) ( Figure 5A ), and dramatically increased Rap1-induced activation ( Figure 5A ). In sharp contrast, RapL/NORE1B, alone or in combination with active Rap1A, did not affect the activation of aIIbb3 ( Figure 5A ). RIAM is required for Rap1-induced aIIbb3 activation, because shRNAmediated knockdown of RIAM reduced Rap1A-induced talin-dependent integrin activation ( Figure 5B ). The specificity of this result was confirmed by the failure of control shRNA to block activation ( Figure 5B ) and by reconstitution with a RIAM construct that contained seven base mismatches with the shRNA (Figure S4 ). To examine the mechanism of RIAM-mediated activation, we assessed the association of RIAM with talin. RIAM coimmunoprecipitated with talin and aIIbb3, and the association was strongly stimulated by cotransfection of Rap1A(G12V) ( Figure 5C ). Furthermore, RIAM was colocalized with clustered, membrane-associated talin in Rap1A(G12V)-transfected cells ( Figure 5D ). Thus, RIAM mediates the formation of a Rap1-induced integrin activation complex, containing talin and RIAM, that binds to and activates the integrin.
The foregoing experiments showed that constitutively activated Rap1A(G12V) could drive the association of RIAM with talin. We wished to assess the interaction of these two proteins in response to physiological stimuli. We first examined the potential colocalization of these talin and RIAM in response to cell adhesion to the extracellular matrix. When A5 cells were cotransfected with talin and RIAM and permitted to adhere to fibrinogen, they initially extended lamellipodia, leading to spreading, and then formed typical talin-containing focal adhesions. During the initial spreading, there was complete colocalization of talin with RIAM in the lamellipodia, a site known to contain activated integrins [30, 31] (Figure 6A) . Some of the talin-containing focal adhesions initially contained RIAM ( Figure 6A ) but at later times (>2 hr after attachment), the mature focal and fibrillar adhesions were devoid of RIAM ( Figure 6A and data not shown). To examine these interactions when all proteins were present at natural abundance, we visualized the localization of endogenous talin and RIAM immunostaining in murine fibroblasts attaching to fibronectin. As in the transfected CHO cells, immunofluorescent staining for RIAM and talin extensively localized in lamellipodia and early focal adhesions, whereas mature focal adhesions frequently lacked RIAM ( Figure 6B and data not shown). Finally, we exploited the observation that Figure 6 . Association of RIAM and Talin in Spreading CHO Cells, Fibroblasts, and Stimulated Platelets (A) Association of RIAM and talin during aIIbb3-mediated cell spreading on fibrinogen. CHO-A5 cells expressing recombinant talin-GFP and RIAM-Myc were permitted to adhere to fibrinogen-coated coverslips for 2 hr and were stained with anti-myc to reveal RIAM (red) and talin-GFP (green) localization and were observed by epifluorescence microscopy. The scale bar represents 10 mm. Yellow arrows and arrowheads indicate talin and RIAM colocalized in focal adhesion or lamellipodia, respectively. Green arrowheads indicate fibrillar adhesion containing talin, but lacking RIAM. (B) Association of endogenous talin and RIAM staining in fibroblasts. NIH 3T3 fibroblasts were permitted to attach to fibronectin-coated coverslips for 15 min and were then double stained for talin and RIAM. The scale bar represents 10 mm. Note colocalization of staining in focal complexes and in some focal adhesions, but lack of RIAM staining in more mature fibrillar adhesions and larger focal adhesions. (C) Association of RIAM antigen and talin in stimulated platelets. A suspension of washed human platelets was incubated at 37 C for 1 min in the presence (TRAP) or absence (middle column) of 200 mM thrombin receptor agonist peptide. After solubilization in 1% NP40, the resulting lysates were immunoprecipitated with anti-talin (8d4) or irrelevant IgG, the resulting precipitates were resolved by SDS-PAGE, and western blots were probed with polyclonal anti-RIAM or anti-talin.
Rap1B is abundant in human platelets and is activated in response to stimulation of the thrombin receptor [32] . When the human thrombin receptor was stimulated with thrombin receptor agonist peptide (TRAP) [33] , containing the sequence SFFLRN, and immunoprecipitated with a talin antibody, RIAM immunoblots revealed a talin-associated protein in the stimulated but not the resting platelets ( Figure 6C ). Thus, in both platelets and fibroblasts, talin associates with RIAM coincident with b3 and b1 integrin activation.
Integrin activation controls cell adhesion, migration, and extracellular-matrix assembly, thus contributing to angiogenesis, tumor-cell metastasis, inflammation, the immune response, and hemostasis [1, 3] . Talin binding to integrin b cytoplasmic domains is a final step in integrin activation [8] . Here, we described a synthetic strategy to reconstruct the signaling pathway between PMA and the activation of integrin aIIbb3 and used this strategy to map connections between an agonist and integrin activation (Figure 7) . Certain key components of this pathway appear to be widely used in many cellular contexts and with many integrins: These components are talin [8] , Rap1 [22] , and RIAM [28] , or their paralogs. These proteins participate in the formation of an integrin activation complex that enables the unmasking of the integrin activating function of talin; this function does not require proteolytic cleavage or phosphorylation of talin. As shown here, variations in cellular abundance of the components of the integrin activation complex or in their regulators, such as PKCa, can then account for the celltype specificity of integrin activation. Indeed, it is now possible to use this core pathway ( Figure 7) as a template to integrate and rationalize a hitherto fragmented literature connecting different agonists and signaling pathways that control integrin activation. This newfound ability to synthetically reconstruct these pathways in heterologous cells will enable a quantitative and mutational analysis of the contributions of each component of the pathway and provides a ready means to discover and analyze new modulators of integrin activation.
Experimental Procedures
Flow Cytometry PAC1 binding was measured by two-color flow cytometry as previously described [11] . In brief, 24 hr after transfection, cells were harvested and were incubated first with 0.1% PAC1 ascites in the presence of the competitive inhibitor Ro43-5054 at 1 mM or anti-LIBS6 ascites and then with R-phycoerythrin-conjugated goat anti-mouse IgM antibody on ice. PAC1 bindings were then measured with a FACScan (Becton Dickinson, Mountain View, California) flow cytometer, and the collected data were analyzed with CellQuest software (Becton Dickinson). To obtain numerical estimates of integrin activation, we calculated an activation index (AI), defined as 100 3 (F o 2 F r )/(F o LIBS6 2 F r ), where F o is the median fluorescence intensity (MFI) of PAC1 binding, F r is the MFI of PAC1 binding in the presence of competitive inhibitor (Ro43-5054, 1 mM), and F o LIBS6 is the MFI of PAC1 binding in the presence of 2 mM anti-LIBS6.
PAC-1 Fab binding to cells was assessed by a similar flowcytometric method as previously described [25, 34] . For maximum integrin activation, cells were incubated with 1 mM MnCl 2 . FN (9-11) binding to endogenous integrin a5b1 was assayed by two-color flow cytometry as described above for PAC-1 binding. Biotinylated FN (9-11) staining in the presence of 5 mM EDTA was used to estimate nonspecific binding. In addition, 1 mM Ro44-9883 (Hoffmann-LaRoche, Basel, Switzerland) was added to the cells during the incubation with biotinylated FN (9-11) to eliminate any FN (9-11) binding to integrin aIIbb3.
Subcellular Fractionation
CHO cells were transfected with cDNAs encoding HA-talin or HAtalin plus HA-Rap1A (G12V). Twenty-four hours after transfection, these cells were subjected to the subcellular fractionation as described previously [35] . Detailed procedures are described in the Supplemental Data.
Platelet Preparation
Platelets were isolated from fresh ACD-anticoagulated human blood and washed as previously described [16] with the addition of 10 mM E64, a calpain inhibitor, to each of the wash and final suspension buffers.
Coimmunoprecipitation and Western Blotting
Coimmunoprecipitations and western-blotting procedures are described in the Supplemental Data.
Clustering of Talin-GFP in Suspension Cells A5 (aIIbb3-expressing CHO cells) cells transfected with PKCa and talin-GFP were serum-starved and maintained in suspension in 1%BSA/DMEM for 3.5 hr. Cells were then treated with dimethyl sulfoxide (DMSO) or with 100 nM PMA for 10 min and fixed in suspension with 3.7% formaldehyde. After washes with PBS, cells were mounted on coverslips with SlowFade antifade reagent (Molecular Probes S-7461) and examined as described below.
Coclustering of aIIbb3 Integrin or RIAM-Myc with Talin-GFP CHO-A5 cells transfected with talin-GFP, or with talin-GFP and RIAM-Myc, with or without RapV12, were adhered on fibrinogencoated coverslips for 2 hr in complete Dulbecco's modified Eagle's medium (DMEM). To label aIIbb3 integrins, 40 mg/ml D57 monoclonal antibody were incubated with the cells for 20 min prior to fixation with 3.7% formaldehyde in PBS. For staining of RIAM-Myc, cells Depicted are core connections between agonists and integrins. Agonist receptors (e.g., G protein-coupled receptors, tyrosine-kinasecoupled receptors [37, 38] ) induce the formation of diacylglycerol (DAG) and increased Ca 2+ leading to the activation and/or translocation of active GTP bound Rap1 to the plasma membrane via activation of protein kinase C (PKC) [17] or a Rap guanine nucleotide exchanger (Rap-GEF) [39] . At the plasma membrane, activated Rap interacts with RIAM [28] , leading to the recruitment of talin to form the integrin activation complex, thus unmasking the integrin binding site in talin F3 leading to integrin activation.
were fixed with 3.7% formaldehyde, permeabilized in 0.1% Triton X-100 for 5 min, blocked with 1%BSA/PBS for 1 hr, and incubated with 1:100 dilution c-Myc monoclonal antibody (Clontech) in 1%BSA/1% normal goat serum/PBS overnight at 4 C. Subsequently, the coverslips were incubated with TRITC-conjugated goat anti-mouse secondary antibody (Santa Cruz) for 1 hr in 1%BSA/PBS, washed, and slide-mounted in Prolong Gold antifade reagent (Molecular Probes) for imaging as described below.
Epi-Fluorescent Imaging
Adherent cells were imaged with a 603 oil immersion objective on a Nikon Eclipse TE2000-U microscope. Suspension-fixed cells were imaged at 0.2 um section intervals with a 603 oil immersion objective on a Nikon Eclipse TE2000-U microscope controlled by SlideBook imaging software. Images were subsequently deconvoluted with a nearest-neighbor algorithm and shown as a maximal projection of Z sections (as in Figure 1D 
